New hair loss drug shows promise in early trial
NCT ID NCT06393452
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 14 times
Summary
This study tested a new medication called PP405 for common hair loss (androgenetic alopecia) in 78 adults aged 18 to 55. The trial had two parts: a 28-day blinded phase comparing PP405 to a placebo, followed by a 3-month open-label phase where everyone received the drug. The main goals were to check safety and how the body processes the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Dermatology & Clinical Research Institute
Encinitas, California, 92024, United States
-
Clinical Trials Research Institute
Thousand Oaks, California, 91320, United States
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
DermResearch
Austin, Texas, 78759, United States
-
Jordan Valley Dermatology Center
South Jordan, Utah, 84095, United States
-
Minnesota Clinical Study Center
New Brighton, Minnesota, 55112, United States
-
Stride Clinical Research LLC
Sugar Land, Texas, 77479, United States
-
Virginia Clinical Research, Inc.
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.